Rafael A. Rodriguez, a director at Neogen Corp, has recently increased his stake in the company by acquiring additional shares through restricted stock units and stock options. This acquisition, reported in a filing on October 2, 2026, is significant as it underscores the commitment of key executives to the company's growth and stability.
Background
Neogen Corp, identified by the Central Index Key (CIK) 0000711377, specializes in the production of in vitro and in vivo diagnostic substances. The company is incorporated in Michigan and is publicly traded under the ticker symbol NEOG. Neogen operates within the life sciences sector, specifically focusing on diagnostic products and services.
What the Filing Says
According to the filing (accession number 0000711377-26-000026), Rodriguez acquired 9,804 restricted stock units on October 1, 2026, at a price of $12.24 per share. Following this transaction, he now owns a total of 30,625 shares directly. Additionally, he exercised options to buy 20,558 shares of common stock at the same price, further increasing his ownership in the company.
Impact
This increase in ownership may influence investor perception of Neogen Corp, as it reflects the confidence of its leadership in the company's prospects. Rodriguez's actions may also encourage other investors to consider their positions in Neogen, particularly in a competitive landscape.
What's Next
The filing does not say what happens next.